ORAL CONTRACEPTIVES

Background

- 1. Available since 1960
 - o Initial estrogen dose 150 mcg
 - o Current estrogen dose 20-50 mcg (<35 mcg of ethinyl estradiol is standard)
- 2. Most commonly used birth control in the United States

Contraindications

- 1. Relative
 - o Gallbladder disease
 - Interacting drugs (anticonvulsants, medications that increase potassium (ACEI, ARBs, K+ sparing diuretics) if using drospirenone containing pills like Yaz, Yasmin)
 - o Obese women >35 y/o
 - Pregnancy or lactation <6 weeks postpartum⁴
- 2. Absolute
 - Previous thromboembolism or stroke⁴
 - Cardiac or vascular disease⁴
 - Uncontrolled HTN⁴
 - Liver Disease
 - History of estrogen-dependent tumor (breast, endometrial)
 - Undiagnosed abnormal uterine bleeding
 - \circ Smokers >35 y/o⁴
 - Migraine headaches with aura⁴
 - o Known thrombogenic mutations

Types

- 1. Combined OCP
 - Estrogen is ethinyl estradiol
 - Several types of progestins
 - Levonorgestrel
 - Norethindrone
 - Drospirenone
 - Ethynodiol diacetate
 - Newer progestins:
 - Norgestimate and Desogestrel
 - Appear to have least androgen activity
 - Less side effects and metabolic complications
 - Monophasic (Loestrin, Lo-Ovral, Ortho-cept, Ortho-Novum, Modicon, Demulen)⁶
 - Same dose of estrogen and progestin for 21 days
 - Multiphasic (Ortho-Novum 7/7/7, Ortho Tri-Cyclen, Ortho Tri-Cyclen Lo Triphasil)⁶
 - Varying dose of estrogen, progestin or both
 - o Continuous (Seasonale) ⁶
 - Active pills for 3 months with one pill-free week
 - o Low dose (Loestrin, Ortho Tri-Cylcen Lo) ⁶

- 20-25 mcg ethinyl estradiol
- Moderate dose ⁶
 - 30-35 mcg ethinyl estradiol
- o High dose (Demulen 1/50) ⁶
 - 50 mcg ethinyl estradiol
- 2. Progestin only pills (Micronor, Nor-QD)
 - o 35mg Norrthindone

Mechanism of Action

- 1. Inhibition of ovulation and decreased receptivity to implantation
 - o Estrogen
 - Inhibits FSH, regulates bleeding to occur at scheduled intervals⁵.
 - o Progestins
 - Inhibit LH and FSH, thicken cervical mucus, inhibit implantation via endometrial thinning and atrophy.
- 2. Approximately 2% of cycles with spontaneous ovulation on low dose pills

Effectiveness

- 1. Effectiveness of over 99% if taken correctly
 - o Typical use: 3-5% failure rate
- 2. Noncompliance with daily pill taking compromises efficacy
- 3. Effectiveness of OCPs reduced by
 - Anticonvulsants
 - Barbiturates, carbamazepine, phenytoin, primidone
 - **Antibiotics**
 - Rifampin, tetracycline, griseofulvin
- 4. Effectiveness of medications reduced by OCPs
 - o Anticonvulsants
 - o Imipramine
 - o Insulin
 - Theophylline

Method of Use

- 1. Starting pills
 - No pelvic exam necessary before prescribing. Effective counseling about efficacy, appropriate use, expected side effects and risk required⁵.
 - Ouick start
 - Take first pill the day they are prescribed
 - Sunday start
 - Take first pill the Sunday after next menses
- 2. Use back-up form of contraception for at least seven days after first starting pill⁵
- 3. Follow-up visits not necessary unless co-morbid condition such as HTN⁵.
- 4. Missed pills
 - Use back-up contraception for at least 7 days if >2 missed pills
 - o Take missed pill as soon as possible and then resume pills as prescribed
- 5. Progestin only pill
 - Need to be taken at the same time every day
- 6. Hormonal emergency contraception: take within 12 hours after intercourse

- o Plan B
- Combined OCP
 - 4 pills of OCPs containing 30-35mcg ethinyl estradiol, repeat in 12 hours
 - 5 pills of OCPs containing 20mcg ethinyl estradiol, repeat in 12 hours

Side Effects

- 1. Serious- Uncommon
 - Venous thromboembolism (DVT, PE)
 - Increasing estrogen dose related to higher risk
 - 3-6x increase in incidence (SOR:B)⁴
 - Ischemic stroke
 - 1.5x higher in women who smoke and take OCPs
 - 2-6x higher among women with Hx of migraine with aura (SOR:B)⁴
 - Increasing estrogen dose related to higher risk
 - Hypertension
 - Myocardial Infarction
 - o Clotting disorders
 - Gallbladder disease
 - o Liver Adenoma
 - o Changes in lipid and glucose metabolism
 - Increased risk of cervical cancer risk after 5 yrs of combination contraceptive use with adjustment for HPV infection. (SOR:B)⁴

2. Common

- o Nausea
- Breast tenderness
- Headache
 - Low-dose pill (<20 mcg) can improve above symptoms
- Breakthrough bleeding/ spotting
 - Common in first three months on the pill
 - 1. Avoid changing pills until after 3 months
 - 2. Decreases with increasing estrogen dose Consider increasing to 30 or 35 mcg pill if on 20 mcg pill
 - May try different type of progestin
- Depression/other mood disturbance
- Decreased sexual desire

Benefits

- 1. Decreased acne (Ortho Tri-Cyclen, Ortho Tri-Cyclen Lo, Ortho-cept) (SOR:A)⁴
- 2. Decreased benign breast disease (fibrocystic and fibroadenomatous)
- 3. Decreased iron-deficient anemia
- 4. Potentially decreased incidence of PID, ectopic pregnancy
- 5. Endometriosis
 - o Pills decrease symptoms by inhibiting ovulation

6. PCOS

- OCPs introduce cycle control
- Decrease incidence of cysts

- o Decrease androgens
- o Caution due to possible worsening of insulin resistance

7. Dysmenorrhea (SOR:B)⁴

Combination contraceptives decrease menstrual cramping

8. Cancer prevention

- Ovarian cancer
 - 50% decrease with use >5 years
- Endometrial cancer
 - 70% decrease with 12 years of use
- Colorectal cancer
 - Lower incidence, without regard to duration of combination contraceptive use (SOR:B)⁴

Alternatives

- 1. Transvaginal contraceptive ring
 - Recommend to women who want fewer days of menstrual bleeding and have trouble remembering to, or prefer not to, take daily pill

2. IUD

- Levonorgestrel-releasing intrauterine device (IUD). Effective for 5 years⁵.
- May cause abnormal bleeding for 3-6 months after insertion followed by possible amenorrhea. Beneficial for menorrhagia, dysmenorrheal, endometriosis and adenomyosis related pain⁵.
- 3. Implantable contraception
 - Releases etonogestrel (active metabolite of desogestrel). Effective for 3 years⁵.
 - May cause abnormal bleeding patterns⁵.

4. Depo-Provera

- o Progestin-only. Requires injection every 3 months⁵.
- o Common side effects include abnormal bleeding patterns and weight gain⁵.
- Contraceptive of choice for women with seizure disorders and sickle cell disease⁵.
 - The level appears to raise seizure threshold⁵
 - Depo-provera stabilizes RBC membrane⁵
- May be of benefit for patients with iron deficiency anemia, dysmennorhea and ovarian cysts⁵.
- o Decreases endometrial carcinoma incidence by 80%⁵.

References

- 1. Hatcher RA, Guillebaud J. The Pill: combined oral contraceptives. In: Hatcher RA, Trussell J, Stewart F, et al (eds). Contraceptive technology, 17th ed. New York, NY: Ardent Media, Inc; 1998:405-6.
- 2. Cerel-Suhl SL, Yeager BF. Update oral contraceptive pills. American Family Physician 1999;60:2073-84. www.aafp.org/afp/991101ap/2073.html
- 3. Ellertson, C, Webb A, Blanchard K, et al. Modifying the Yuzpe regimen of emergency contraception: a multicenter randomized controlled trial. Obstet Gynecol 2003: 101:1160-7

- 4. Roederer MW, Blackwell JC, Blenning C. Risks and Benefits of Combination Contraceptives. American Family Physician, FPIN's Clinical Inquiries. 2006: 1;74(11): 1915-1916.
- 5. Blumenthal PD, Edelman A. Hormonal Contraception. Obstetrics and Gynecology 2008; 112:670-84.
- 6. Frye CA. An Overview of Oral Contraceptives, Mechanism of action and clinical use. Neurology 2006: 66 (Suppl 3):S29-S36.

Evidence-Based Inquiry

- 1. What are the risks of oral contraceptives for patients with cardiovascular disease risk factors?
- 2. Do antibiotics interfere with the efficacy of oral contraceptives?
- 3. What are the relative risks and benefits of progestin-only contraceptives?
- 4. What is the risk of adverse outcomes in a woman who develops mild hypertension from OCs?
- 5. What are the relative risks and benefits of combination contraceptives?
- 6. What hormonal contraception is most effective for obese women?
- 7. How does VTE risk for the patch and vaginal ring compare with oral contraceptives?
- 8. What is the risk of breast cancer in women who take oral contraceptives?

PURLs

1. When to suggest this OC alternative

Authors: Elisabeth Hyde, MD, & Juan Qui, MD, Penn State Hershey Medical Center, PA

Editor: Michael Flanagan, MD, Penn State Hershey Medical Center, PA